Latest Daunorubicin Stories
Will a drug used to treat childhood acute lymphoblastic leukemia and other pediatric cancers cause heart problems later in life?
NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ -- Recent findings published in the scientific journal Leukemia Research (http://www.sciencedirect.com/science/article/pii/S0145212611002505), showed that when combined with standard anti-leukemia agents, the biological activity of Leukothera(TM), a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects.
PRINCETON, N.J., Nov.
PRINCETON, N.J., Oct.
PRINCETON, N.J., Sept. 1 /PRNewswire/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.
PRINCETON, N.J., June 21 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc. (Nasdaq: CEPH).
PRINCETON, N.J., June 14 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen.
PRINCETON, N.J., June 7 /PRNewswire/ -- Celator Pharmaceuticals today announced that a subset analysis of data from its Phase 2 study in newly diagnosed acute myeloid leukemia (AML) demonstrates that CPX-351 (Cytarabine:Daunorubicin) Liposome Injection can induce complete remissions in patients following the failure of induction therapy with conventional cytarabine and daunorubicin (the "7+3" regimen).
PRINCETON, N.J., May 3 /PRNewswire/ -- Celator Pharmaceuticals, Inc.
PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC...
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.